{"schema_version":"1","generated_at":"2026-11-04T01:41:35.083Z","data_as_of":null,"url":"https://www.findmykol.com/kol/kert-sabbath","json_url":"https://www.findmykol.com/kol/kert-sabbath/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"kert-sabbath","name":"Kert Sabbath","credential":"MD","specialty":"Hematology / Oncology","specialty_raw":"Hematology & Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"institution":"Yale Cancer Center","institution_url":"https://www.findmykol.com/institution/yale-school-of-medicine","city":"Waterbury","state":"CT","region":{"label":"Northeast","url":"https://www.findmykol.com/region/northeast"}},"identifiers":{"npi":"1831121052","openalex":"A5110446742"},"summary":"Kert Sabbath is an Oncology physician affiliated with Yale Cancer Center. OpenAlex indexes 43 publications with 3,638 citations (h-index 14).","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":43,"cited_by_count":3638,"h_index":14,"latest_activity_year":2026,"source":"works"},"payments":{"company_count":7,"program_years":{"first":2021,"last":null},"rows_total":13,"shown":3,"withheld":10,"rows":[{"payer":"Novocure Inc.","program_year":2025,"amount_usd":155.1,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1831121052"},{"payer":"Coherus Biosciences Inc.","program_year":2024,"amount_usd":142.27,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1831121052"},{"payer":"Helsinn Therapeutics (U.S.)","program_year":2023,"amount_usd":6685,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1831121052"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1831121052","source":"payments"},"prescribing":{"data_year":2024,"areas_total":9,"areas_shown":3,"areas":[{"area":"Cancer & immunology","share_pct":40.9,"classes_total":6,"classes":[{"class":"Aromatase Inhibitor","setting":"prescribed","share_pct":13.6,"drugs":[{"name":"Anastrozole","share_pct":90.8},{"name":"Letrozole","share_pct":9.2}],"max_beneficiaries":null},{"class":"Thalidomide Analog","setting":"prescribed","share_pct":7.1,"drugs":[{"name":"Revlimid","share_pct":81},{"name":"Pomalyst","share_pct":19}],"max_beneficiaries":null}]},{"area":"Blood & clotting","share_pct":19.8,"classes_total":3,"classes":[{"class":"Factor Xa inhibitor","setting":"prescribed","share_pct":14.7,"drugs":[{"name":"Eliquis","share_pct":67.7},{"name":"Xarelto","share_pct":32.3}],"max_beneficiaries":14},{"class":"Vitamin K antagonist","setting":"prescribed","share_pct":3.3,"drugs":[{"name":"Warfarin Sodium","share_pct":100}],"max_beneficiaries":null}]},{"area":"Nervous system","share_pct":12.1,"classes_total":5,"classes":[{"class":"Opioid Agonist","setting":"prescribed","share_pct":4.6,"drugs":[{"name":"Tramadol Hcl","share_pct":39},{"name":"Oxycodone Hcl","share_pct":31.7},{"name":"Fentanyl","share_pct":29.3}],"max_beneficiaries":null},{"class":"Phenothiazine","setting":"prescribed","share_pct":3.5,"drugs":[{"name":"Prochlorperazine Maleate","share_pct":100}],"max_beneficiaries":22}]}],"care_setting":{"dominant":"office","data_year":2024,"office_pct":100,"facility_pct":0},"source":"medicare"},"publications":{"total":43,"shown":5,"withheld":38,"matched_by":"OpenAlex author record","recent":[{"title":"Abstract PS2-09-28: Use of DiviTum®TKa assay to assess CDK4/6 inhibitor medication compliance and drug interactions","year":2026,"journal":"Clinical Cancer Research","source_url":"https://doi.org/10.1158/1557-3265.sabcs25-ps2-09-28","status":"verified"},{"title":"PA-341 Patient-Reported Quality of Life and Real-World Outcomes with Use of Daratumumab Regimens in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: A Multicenter Study","year":2026,"journal":"Clinical Lymphoma Myeloma & Leukemia","source_url":"https://doi.org/10.1016/s2152-2650(26)03704-3","status":"verified"},{"title":"PA-322 Open-Label, Single-Arm Phase Ib/II Study of Immune Combination Therapy with Belantamab Mafodotin and Elotuzumab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)","year":2026,"journal":"Clinical Lymphoma Myeloma & Leukemia","source_url":"https://doi.org/10.1016/s2152-2650(26)03685-2","status":"verified"},{"title":"Abstract P4-03-29: Patient reported anxiety levels during ctDNA surveillance in early stage triple negative and hormone positive breast cancer","year":2025,"journal":"Clinical Cancer Research","source_url":"https://doi.org/10.1158/1557-3265.sabcs24-p4-03-29","status":"verified"},{"title":"Target antigen density may impact clinical response in patients with relapsed/refractory multiple myeloma undergoing treatment with elotuzumab and belantamab mafodotin","year":2025,"journal":"Blood","source_url":"https://doi.org/10.1182/blood-2025-7578","status":"verified"}],"source":"works"},"contact":{"address_1":"1075 CHASE PKWY","address_2":"SUITE B","city":"Waterbury","state":"CT","zip":"067082948","phone":"203-755-6311","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1831121052","source":"identity"},"similar":[{"name":"Ian Krop","slug":"ian-krop","institution":"Yale Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/ian-krop","json_url":"https://www.findmykol.com/kol/ian-krop/profile.json"},{"name":"Harriet Kluger","slug":"harriet-kluger","institution":"Yale Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/harriet-kluger","json_url":"https://www.findmykol.com/kol/harriet-kluger/profile.json"},{"name":"Stephanie Halene","slug":"stephanie-halene","institution":"Yale Cancer Center","specialty":"Hematology","url":"https://www.findmykol.com/kol/stephanie-halene","json_url":"https://www.findmykol.com/kol/stephanie-halene/profile.json"},{"name":"John Kunstman","slug":"john-kunstman","institution":"Yale Cancer Center","specialty":"Surgical Oncology","url":"https://www.findmykol.com/kol/john-kunstman","json_url":"https://www.findmykol.com/kol/john-kunstman/profile.json"},{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Beth Karlan","slug":"beth-karlan","institution":"University of California, Los Angeles","specialty":"Gynecologic Oncology","url":"https://www.findmykol.com/kol/beth-karlan","json_url":"https://www.findmykol.com/kol/beth-karlan/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":10,"publications":38}},"sources":{"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2011-12-21","collected_at":"2026-11-03T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2024}},"methodology_url":"https://www.findmykol.com/about#methodology"}